drugset
Drugs / nexiguran ziclumeran
last change Nov 2025 re-read 3 minutes ago

nexiguran ziclumeran

Developed for
familial amyloid neuropathy · polyneuropathy
Investigated by
Intellia Therapeutics · Regeneron Pharmaceuticals

Trials 1

today NCT06672237 · Ph 3
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06672237 Nov 2024 → Jul 2027 expected familial amyloid neuropathy, inherited neurodegenerative disorder, polyneuropathy Intellia Therapeutics Recruiting No outcome recorded

Press releases naming this drug 11 releases

DateIssuerRelease
2025-11-10 Intellia Therapeutics Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy intelliatx.com ↗
2025-10-27 Intellia Therapeutics Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) intelliatx.com ↗
2025-09-25 Intellia Therapeutics Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy intelliatx.com ↗
2025-09-22 Intellia Therapeutics Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy intelliatx.com ↗
2025-05-18 Intellia Therapeutics Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting intelliatx.com ↗
2025-04-03 Intellia Therapeutics Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy intelliatx.com ↗
2025-03-26 Intellia Therapeutics Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy intelliatx.com ↗
2025-01-09 Intellia Therapeutics Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) intelliatx.com ↗
2024-11-25 Intellia Therapeutics Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy intelliatx.com ↗
2024-11-16 Intellia Therapeutics Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis intelliatx.com ↗
2024-10-01 Intellia Therapeutics Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions intelliatx.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as nexiguran ziclumeran ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672237 ↗
Route Intravenous “nexiguran ziclumeran 55 mg by single IV infusion” NCT06672237 ↗